References
- Lynparza 100mg and 150mg film-coated tablets Summary of Product Characteristics.
https://www.medicines.org.uk/emc/product/9204/smpc. [October 2019]. Accessed July 2020. - NICE. NICE guidance on olaparib for maintenance treatment of ovarian, fallopian tube or peritoneal cancer that has a BRCA germline mutation after response to first-line platinum-based chemotherapy.
https://www.nice.org.uk/guidance/indevelopment/gid-ta10257. [August 2019]. Accessed July 2020. - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer TA620 | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ta620. [January 2020]. Accessed July 2020.
- Scottish Medicines Consortium. Olaparib 100mg and 150mg film-coated tablets (Lynparza). SMC No. (2209).
https://www.scottishmedicines.org.uk/media/4940/olaparib-lynparza-final-november-2019- for-website.pdf. [November 2019]. July 2020. - Scottish Medicines Consortium. Re-submission - olaparib, 50mg, hard capsules (Lynparza). SMC No. (1047/15).
https://www.scottishmedicines.org.uk/files/advice/olaparib_Lynparza_Resub_FINAL_Oct_2016_revised_201016_for_ website.pdf. [October 2016]. Accessed July 2020. - Lynparza 50 mg hard capsules Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/6821/smpc. [October 2019]. Accessed July 2020.
- Moore, K. et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
- Capoluongo, E. et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Semin. Oncol. 44, 187–197 (2017).
- Ozols, R. F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 21, 3194–3200 (2003).
- Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).
- Bookman, M. A. et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. J. Clin. Oncol. 27, 1419–1425 (2009).
- Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473–2483 (2011).
- Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861 (2014).
- Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017).
- Moore, K. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. Supplementary appendix. N.Engl. J. Med. 379, (2018).
- Moore, K. et al. 2018. Oral presentation LBA7_PR, ESMO.
- Ledermann, J. et al. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. N. Engl. J. Med. 366, 1382–1392 (2012).
- Friedlander, M. et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br. J. Cancer 119, 1075–1085 (2018).
- Friedlander, M. & Matulonis, U. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy (Supplementary appendix). Br. J. Cancer 119, Appendix (2018).
- Robson, M. et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 377, 523–533 (2017).